Patients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in Focal Segmental Glomerulosclerosis (FSGS)

Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan vs Irbesartan in Patients With Immunoglobulin A Nephropathy